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ABSTRACT:  
Background: Hospitalizations due to medical and surgical complications of substance use disorder (SUD) 
are rising. Most hospitals lack systems to treat SUD, and most people with SUD do not engage in 
treatment after discharge.  
Objective: Determine the effect of a hospital-based addiction medicine consult service, the Improving 
Addiction Care Team (IMPACT), on post-hospital SUD treatment engagement 
Design: Cohort study using multivariable analysis of Oregon Medicaid claims comparing IMPACT patients 
with propensity-matched controls.  
Participants: 18-64 year-old Oregon Medicaid beneficiaries with SUD, hospitalized at an Oregon hospital 
between July 1, 2015 and September 30, 2016. IMPACT patients (n=208) were matched to controls 
(n=416) using a propensity score that accounted for SUD, gender, age, race, residence region, and 
diagnoses. 
Interventions: IMPACT included hospital-based consultation care from an interdisciplinary team of 
addiction medicine physicians, social workers, and peers with lived experience in recovery. IMPACT met 
patients during hospitalization; offered pharmacotherapy, behavioral treatments, and harm reduction 
services; and supported linkages to SUD treatment after discharge. 
Outcomes: Healthcare Effectiveness Data and Information Set (HEDIS) measure of SUD treatment 
engagement, defined as two or more claims on two separate days for SUD care within 34 days of 
discharge. 
Results: Only 17.2% of all patients were engaged in SUD treatment before hospitalization. IMPACT 
patients engaged in SUD treatment following discharge more frequently than controls (38.9% vs. 23.3%, 
p<0.01; aOR 2.15, 95% Confidence Interval [CI] 1.29-3.58). IMPACT participation remained associated 
with SUD treatment engagement when limiting the sample to people who were not engaged in 
treatment prior to hospitalization (aOR 2.63; 95% CI 1.46-4.72).  
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Conclusions: Hospital-based addiction medicine consultation can improve SUD treatment engagement, 
which is associated with reduced substance use, mortality, and other important clinical outcomes.  
National expansion of such models represents an opportunity to address an enduring gap in the SUD 
treatment continuum. 
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INTRODUCTION 
Hospitals are increasingly filled with people suffering from medical complications of substance use 
disorders (SUD) (1, 2). One in seven patients in general hospitals have a substance use disorder (3) and 
hospitalizations for opioid- and methamphetamine-related diagnoses are surging (4-6). Patients with 
SUD have longer lengths of stay, higher costs (6), and higher readmission rates (3). Over the last decade, 
costs related to SUD-associated hospitalizations have quadrupled, with an estimated $15 billion due to 
hospitalizations related to opioid use disorder in 2012 alone (2).  
 
Despite frequent hospitalizations and high healthcare costs, most hospitalized patients with SUD are not 
engaged in SUD care before hospitalization, and most hospitals do not treat SUD during the acute 
inpatient encounter (2, 7). Failure to treat SUD in hospitals leads to untreated withdrawal, failure to 
complete recommended medical therapy, and high rates of against medical advice discharge (8-10). 
Though there are decades of evidence showing the effectiveness of medication for opioid (11) and 
alcohol use disorders (12), most hospitals lack expertise and systems to treat SUD and do not effectively 
connect people to treatment after discharge (13). Barriers include lack of addiction medicine expertise, 
regulatory concerns, stigma, and silos between hospital and community SUD treatment settings (8, 14).  
 
Hospitalization is a crucial potential juncture to engage out-of-treatment adults in SUD care (15, 16). 
Hospitalized patients with SUD have nearly twice the rate of hospital readmission and repeat ED use 
within 30 days (3), compared to those without SUD.  And the immediate period after hospital discharge 
is particularly high risk for drug-related death and suicide (17). SUD treatment engagement is associated 
with reduced substance use severity (18-21), higher employment and wages (22), less future criminal 
involvement (21), reduced overdose rates (11), and reduced all-cause mortality (11, 23).  Hospitalization 
can be a reachable moment to initiate and coordinate SUD care. Although medical and surgical 
5 
 
inpatients do not come to the hospital seeking addiction care, a study of hospitalized adults at our 
hospital found that over half of people with high-risk alcohol use and over two-thirds of people with 
high-risk drug use reported wanting to cut back or quit (24). Interventions to improve post-discharge 
SUD treatment engagement are likely to improve outcomes for people with SUD.  
 
Despite a growing literature of the feasibility and importance of hospital-based addictions care (25-29), 
there are no studies using robust causal inference methods to evaluate the effects of inpatient addiction 
medicine consultation on SUD treatment engagement after discharge. A quasi-experimental study at a 
single Boston academic medical center comparing patients who received inpatient addiction medicine 
consultation with those who did not found that patients seen by the consult service were more likely to 
report SUD treatment engagement at 30 and 90 days after discharge (30). While promising, this study 
relied on self-reported outcomes and had 34% loss-to follow up at 30 days and 47% at 90 days. 
Additional rigorous evaluations to understand the effect of hospital-based addiction medicine care on 
post-hospital community SUD treatment are critical for broader adoption and dissemination.  
 
We implemented a previously described interprofessional hospital-based addiction medicine consult 
service called the Improving Addiction Care Team (IMPACT) (8, 24, 31, 32). IMPACT engages adults with 
opioid, alcohol, methamphetamine, and other substances (excluding tobacco use disorder alone) during 
the reachable moment of hospitalization and provides rapid-access pathways to community SUD 
treatment and harm reduction support. The goal of this analysis was to assess post-hospital SUD 
treatment engagement among Oregon Medicaid recipients who received IMPACT care compared to 
propensity score-matched controls. We hypothesized that IMPACT participation would be associated 
with greater post-hospital SUD treatment engagement.  
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METHODS 
Intervention 
IMPACT is a hospital-based addiction medicine consult service that includes care from addiction 
medicine physicians, social workers, and peers with lived experience in recovery. Inpatient medical and 
surgical providers and hospital social workers refer patients with known or suspected SUD to IMPACT. 
IMPACT is open to patients with any SUD (excluding people with tobacco use disorders alone) regardless 
of readiness to change or interest in treatment. Initially IMPACT served patients admitted to medicine, 
family medicine, cardiology services; or patients needing prolonged intravenous antibiotics admitted to 
any hospital service. IMPACT expanded to include surgical services in July 2017. IMPACT medical 
providers and social workers perform an initial comprehensive assessment, including DSM-5 SUD 
diagnosis assessment; elicit patient-centered goals around the acute hospitalization and SUD; initiate 
SUD treatment, including pharmacotherapy and behavioral treatments; and offer harm reduction 
services. IMPACT includes robust referral pathways to post-hospital SUD care and, in some cases, forges 
relationships with rural SUD providers to coordinate post-hospital care (24, 31, 32). Earlier work 
provides a detailed description of the interprofessional team and intervention (24, 32).  
 
During the study window, IMPACT included 0.7 full-time equivalent (FTE) clinical physician time shared 
amongst 5 physicians, 1 social worker, and 2 peer recovery mentors. IMPACT physicians documented a 
median value of 2 patient visits (range 1-33) and social workers a median 3 (1-33) patient visits per 
hospitalization. Intervention intensity depends on patient needs, hospital length-of-stay, and IMPACT 
capacity. 
 
Setting and study design: 
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Earlier research found that IMPACT created system-level change by reframing addiction as a treatable 
chronic disease, increasing provider understanding of how to engage and treat patients with SUD, and 
creating rapid pathways to care (8). As such, a patient- or provider- level randomized trial would not 
adequately isolate the intervention effect.  Thus, we conducted a multivariable analysis comparing 
intervention patients to propensity-matched controls across Oregon hospitals. We used Oregon 
Medicaid claims data, obtained under a data use agreement with the Oregon Health Authority, that 
included physical/behavioral health and pharmacy claims in calendar years 2015-2016. This study was 
approved by the Oregon Health & Science University (OHSU) Institutional Review Board.  
 
Population 
All participants were 18-64 years-old with Oregon Medicaid insurance, had at least one SUD diagnosis 
(not including tobacco use disorder), and were hospitalized at an Oregon hospital between July 1, 2015 
and September 30, 2016. IMPACT patients had confirmed or suspected SUD and were referred by 
medical and surgical providers at a large academic center in Portland, Oregon. Interest in SUD treatment 
was not required for IMPACT participation. Patients initially referred for IMPACT evaluation were 
excluded if a DSM-5 SUD diagnosis was not confirmed. We included individuals with past SUD treatment 
because acute illness and hospitalization can interrupt SUD treatment (33) and precipitate return to use, 
and IMPACT coordinates and supports care continuity for hospitalized patients already engaged in 
treatment. During the study window, IMPACT had 357 referrals. Of those, 269 (75.3%) had Oregon 
Medicaid, of which 264 were eligible for IMPACT and 208 were seen by IMPACT and comprise the 
IMPACT cohort (Figure 1). 
 
We used propensity score matching to reduce bias by ensuring that cases and controls had comparable 
covariate distributions (34). First, we calculated a propensity score using all inpatient admissions with an 
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SUD diagnosis. We calculated a propensity score using backwards stepwise logistic regression and 
accounted for SUD type, gender, age, race, residence region, and diagnoses, including the Chronic Illness 
& Disability Payment System (CDPS) (35) risk score, which consists of 17 distinct disease categories that 
include physical and psychiatric diagnoses. Next, we matched IMPACT participants to potential controls 
matching on mutually exclusive SUD categories. For example, we matched patients with co-occurring 
opioid and methamphetamine use only to controls with co-occurring opioids and methamphetamine 
use. This allowed us to account for polysubstance use. Then, within each exactly matched SUD group we 
nearest-neighbor matched each IMPACT patient to two controls, without replacement, based on 
propensity score.  
 
Measures:  
The primary outcome, was the Healthcare Effectiveness Data and Information Set (HEDIS) National 
Committee for Quality Assurance (NCQA) definition of post-discharge SUD treatment engagement, (36) 
which includes two or more of the following occurring on at least two separate days within 34 days of 
discharge: 1) a filled prescription for medication treatment (e.g. buprenorphine), 2) a procedure code 
for SUD treatment (e.g. methadone administration at an opioid treatment program, behavioral 
treatment for stimulant use disorder), or 3) a clinic visit with an SUD ICD9 or 10 code (appendix). Filled 
prescriptions were limited to FDA-approved medications for SUD (excluding medication for tobacco use 
disorder).  Medications dispensed from a hospital pharmacy at the time of discharge (for example, a 
bridging prescription for buprenorphine) do not appear in Oregon Medicaid claims; instead, they are 
included as part of the inpatient admission. In general, IMPACT’s practice is to provide a 7-14 day bridge 
prescription for buprenorphine, and up to 28 days for oral naltrexone or acamprosate at hospital 
discharge. A single prescription in the 34-days after discharge or one-time administration of a long-
acting injectable medication would appear as a single encounter and not meet criteria for HEDIS 
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treatment engagement. Both of these factors might lead to an under-estimate of post-hospital SUD 
treatment engagement using our primary outcome.  
 
Covariates adjusted for in the final model included SUD treatment engagement in the 34 days prior to 
hospitalization, SUD type (opioid SUD vs. non-opioid SUD), gender, age, race/ethnicity, Portland tri-
county area residence as a surrogate marker for urban versus non-urban healthcare systems, Medicare 
Severity Diagnosis-Related Group (MS-DRG) (37) category,  Chronic Illness & Disability Payment System 
risk score (35).    
 
Analysis 
We used multivariable logistic regression to evaluate the effect of IMPACT participation on treatment 
engagement. Due to small counts for many of the MS-DRGs we collapsed them into clinically meaningful 
groups with sufficient numbers to model. High prevalence of polysubstance use led to sizeable overlap 
when we analyzed the effect of individual substances separately. Hence, we separated patients with any 
opioid use versus others because of the existence of more effective treatment options for opioid use 
disorder. Due to concerns that post-hospital treatment engagement could be driven by prior SUD 
treatment, we also conducted a sensitivity analysis modeling engagement among only those patients 
who had not engaged in SUD treatment in the 34 days prior to hospitalization. We performed data 
management and statistical analysis using Stata version 15.1.  
 
Role of the Funding Source: 
This study was funded by the OHSU School of Medicine. Funders had no role in the design, conduct and 
reporting of this study.  
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RESULTS 
Cases (n=208) and controls (n=416) had similar gender, race and ethnicity, rural residence, age, and 
mean CDPS risk score distribution (Table 1). 60.3% were male, 54.7% were 40 years or older, 29.8% had 
any opioid SUD diagnosis. More cases resided in the Portland tri-county area (82.7% vs. 70.9%). More 
controls had DRGs in the heterogeneous “other” category (40.1% vs. 29.3%). Only 17.2% of all patients 
were engaged in treatment in the 34 days prior to hospitalization, with similar rates among IMPACT 
(12.5-19.2%) and controls (12.3-16.0%). Of the 208 IMPACT patients, 31 received a discharge 
prescription for buprenorphine, 14 for oral naltrexone, 8 for acamprosate, and 18 received injectable 
naltrexone during hospitalization with a plan to continue. At the time of discharge, 56 had a plan to 
continue methadone maintenance. At 34 days, 1 person in IMPACT and 14 people in the control group 
had died. 
 
In the primary analysis, IMPACT patients engaged in SUD treatment following discharge more frequently 
than controls (38.9% vs. 23.3%, p<0.01; adjusted odds ratio [aOR] 2.15, 95% confidence interval [CI] 
1.29-3.58 (Table 2). Predictably, those engaged in treatment before admission had substantially greater 
odds of receiving treatment after discharge (aOR 11.95; 95% CI 6.31-22.65). A sensitivity analysis limiting 
the sample to those without pre-hospital SUD treatment showed similar results, with a significant 
association between IMPACT and engagement in SUD treatment (aOR 2.63, 95% CI 1.46-4.72). Patients 
with opioid use disorder were more likely than those without an opioid use disorder to engage in 
treatment (aOR 1.83, 95% CI 1.03-3.24). 
 
The figure shows the unadjusted proportion of patients receiving treatment in the 6 months before 
hospitalization and within the 34 days after discharge. Treatment engagement is similar in the months 
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before admission and increases following discharge, more for IMPACT patients than controls (39.9% vs. 
23.3%, p<.01) (Figure 2). 
 
DISCUSSION 
Hospitalized Medicaid recipients with SUD who received inpatient addiction medicine consultation had 
greater odds of post-hospital SUD treatment engagement than matched controls. Few patients were 
engaged in SUD care prior to hospitalization, highlighting the role of hospitalization as a reachable 
moment. To our knowledge, this is most rigorously controlled study demonstrating the effectiveness of 
an inpatient addiction medicine consult service in improving SUD treatment engagement, one of the 
enduring gaps in the SUD treatment continuum (38).  
 
Our study extends previous research in several important ways. First, propensity score-matched controls 
provide a rigorous comparison group which alleviates potential bias due to systematic differences in 
treatment groups, (39) and we also controlled for known confounders. Our work builds on a quasi-
experimental study at a Boston academic medical center that compared patients who received inpatient 
addiction medicine consultation with those who did not, finding that patients seen by the inpatient 
consult service were more likely to report SUD treatment engagement at 30 and 90 days after discharge 
(30). While promising, this study was quasi-experimental, relied on self-reported outcomes and had high 
loss-to follow up (34% at 30 days, 47% at 90 days). Second, whereas earlier studies (25-27) measure 
engagement as a single SUD-related encounter, ours ties hospital-initiated care to multiple post-hospital 
treatment encounters using the NCQA HEDIS measure. Third, our study measured treatment 
engagement state-wide across any setting, whereas prior studies measured engagement by self-report 
or referral to a single SUD treatment location (25, 27). Finally, claims data provide a more reliable 
measure of treatment engagement than self-report. 
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Patients with opioid use disorder (OUD) had greater odds of engagement than those with non-opioid 
SUD. We hypothesize that this may be due to greater uptake and effectiveness of medications for OUD 
compared with non-opioid SUD, particularly for methamphetamine use disorder. 
 
Treatment prior to admission was, unsurprisingly, associated with substantial increased odds of 
treatment engagement following hospitalization. One might hypothesize that the effect of an 
intervention such as IMPACT is driven by prior treatment engagement, however a sensitivity analysis 
showed IMPACT had a durable effect amongst patients without prior treatment engagement.  This 
highlights a potential role of inpatient addiction medicine consult services in facility treatment retention 
by avoiding treatment interruption during hospitalization and return to use—another major gap in the 
SUD treatment continuum. 
 
Our study has several important implications. First, hospitals can and should address SUD. Current 
hospital practice, which treats acute medical problems resulting from SUD without addressing the 
underlying cause, is analogous to performing an amputation for a diabetic foot infection without 
providing insulin or referring to outpatient diabetes care. The finding that inpatient addiction medicine 
care increases post-hospital treatment engagement further underscores the need to address SUD during 
hospitalization.       
 
In our study, only 17% of people were engaged in treatment prior to hospitalization. This is consistent 
with national trends showing that only 7.7% of people with any past-year SUD received treatment (40). 
Current reform efforts have focused largely on integrating addictions treatment in primary care. These 
are critical reforms, and long-term success of hospital-based interventions depends on availability of 
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community treatment. However, integrating SUD care in hospitals should not be overlooked. Hospitals 
have potential to engage people who are not engaged in primary care, who are medically complex, 
whose SUD may be particularly severe, and who may be high healthcare utilizers.  
 
Doubling the odds of treatment engagement, with 39% of IMPACT participants engaging in post-hospital 
SUD care, is important. Our outcome measure may underestimate treatment engagement. However, 
the patients that did not connect to treatment warrant consideration. Not all hospitalized adults with 
SUD want treatment, highlighting our continued duty to implement harm reduction practices in 
hospitals and across communities. Ample evidence supports that harm reduction practices make 
substance use safer and ultimately can engage people in treatment (41-44). However, some patients 
may have wanted to engage in treatment and been unsuccessful because of limited transportation, 
housing, criminal justice involvement, and medical illness. Hospital interventions can be catalysts for 
community level change, but alone they cannot address structural barriers such as federal regulations 
limiting methadone access, banning medication for opioid use disorder in jails, and the need for more 
buprenorphine providers. Rural treatment access is another important consideration. Though it did not 
meet the statistical threshold for significance, patients with SUD who resided in areas outside of 
metropolitan Portland less commonly engaged in SUD treatment following discharge, consistent with 
lack of treatment providers, transportation and other barriers that limit access to SUD care in rural 
America (45, 46).  Finally, medical frailty presents a significant challenge to SUD treatment engagement. 
Barriers occur at the level of SUD treatment, where the physical demands of standing in line for 
methadone or participating in groups can represent insurmountable barriers. And post-acute care 
settings such as skilled nursing facilities (SNFs) often force people to choose physical rehabilitation or 
SUD treatment (also often denying people access to SNF altogether based on a history of SUD) (26). In 
this regard, hospital-based addictions medicine consult services have potential to improve SUD 
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treatment retention and relapse prevention through care planning —another major gap in the SUD 
treatment continuum.  
Our study has several important limitations. First, claims data are collected primarily for billing and may 
not accurately reflect all diagnoses. Further, claims do not include non-billable SUD services such as 12-
step meetings, syringe exchange services, or prescriptions dispensed on the day of discharge from a 
hospital pharmacy – a common practice for IMPACT that potentially underestimates its effect. Second, 
the study is not a randomized controlled trial and thus may be influenced by selection bias or unknown 
confounders.  Due to complexities related to when IMPACT was available across different services, we 
do not have data on the total number of patients that could have been eligible for IMPACT.  It is possible 
that providers referred patients who would be more or less likely than controls to engage in SUD 
treatment. For example, providers may have preferentially referred patients who expressed an interest 
in treatment. Alternatively, providers may have referred patients who declined usual care social work 
SUD referrals or who had severe medical or behavioral complications (e.g. disruptive behaviors including 
active in-hospital drug use, leaving against medical advice) associated with lower likelihood of treatment 
engagement. We mitigated this by 1) making IMPACT broadly inclusive (excluding only those who 
refused to speak with us and reducing the risk that only motivated patients entered the study), 2) 
propensity score matching, which can approximate randomization and adjust for unmeasured 
confounders (47, 48), 3) adjusting for covariates and pre-hospital SUD treatment, and 4) using a 
stringent outcome which may under-estimate the true effect of IMPACT. Thirds, we limited our study 
population to adults with Oregon Medicaid; however, Medicaid patients comprise most hospitalized 
patients with SUD (49). Fourth, this was not a blinded study, however we do not expect blinding to 
affect assessment of the outcome, which was measured using administrative data. Fifth, Medicaid 
claims data does not reliably include important social factors such as housing and transportation, so we 
were unable to control for these. Sixth, we were unable to assess follow up among people who lost 
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Medicaid insurance in the 34 days after discharge, which likely had a minimal effect, and in those who 
moved out of Oregon following discharge. Because IMPACT occasionally supported people to connect 
with supportive family and/or treatment out-of-state, this may have underestimated SUD engagement 
in the IMPACT group. Finally, our study was performed in a single state with low racial and ethnic 
diversity and was among the first states to expand Medicaid, which may limit generalizability.  
 
Our study shows that hospitalization can be a place to initiate and engage people in SUD care, however 
more research is needed to understand how to best support long-term treatment retention. Recently 
hospitalized adults may have different treatment needs. Future research examining treatment retention 
among recently discharged adults with SUD is warranted. This research should include those in 
treatment before admission and those who initiated treatment during hospitalization.  
 
Future research should define which components of hospital-based addictions care such as IMPACT are 
most important: for example, for which patients with opioid use disorder is a physician prescribing 
medication or linking to community treatment sufficient, and which patients need peer support or social 
work intervention? Additional research is also needed to understand how to adapt an IMPACT-model to 
different settings with different resources. Finally, future research is needed to assess the effect of 
hospital-based addiction medicine consultation on patient experience, SUD severity, against medical 
advice discharge rates, physical health outcomes, hospital readmissions, healthcare costs, and mortality. 
 
CONCLUSIONS: 
Hospital-based addiction medicine care can improve SUD treatment engagement. National expansion of 
such models represents an opportunity to address one of the enduring gaps in the SUD treatment 
continuum. 
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Table 1: Patient characteristics: IMPACT versus Controls    
      
 
IMPACT 
N=208 
Controls 
N=416 
Total        
N=624 P-valuea 
Characteristic N (%)  
Prior SUD treatmentb 37 (17.8) 70 (16.8) 107 (17.2) 0.76 
SUD Type         
Non-opioid SUDc 146 (70.2) 292 (70.2) 438 (70.2) 1.00 
Any opioid SUDd 62 (29.8) 124 (29.8) 186 (29.8) 1.00 
Male 127 (61.1) 249 (59.9) 376 (60.3) 0.77 
Age 18-39 years 102 (49.0) 181 (43.5) 283 (45.4) 0.19 
Age 40-64 years 106 (51.0) 235 (56.5) 341 (54.7)  
White Non-Hispanic 160 (76.9) 341 (82.0) 501 (80.3) 0.14 
Portland tri-county areae 172 (82.7) 295 (70.9) 467 (74.8) <0.01 
MS-DRG Categoryf         
Alcohol & related complications 44 (21.2) 86 (20.7) 130 (20.8) 0.01 
Endocarditis, osteomyelitis, sepsis 65 (31.3) 116 (27.9) 181 (29.0)  
Skin & soft tissue infections 16 (7.7) 10 (2.4) 26 (4.2)  
Non-valvular cardiovascular 13 (6.3) 17 (4.1) 30 (4.8)  
Orthopedic/Joint 9 (4.3) 20 (4.8) 29 (4.7)  
Other 61 (29.3) 167 (40.1) 228 (36.5)  
  Mean (SD)   
CDPS Risk Scoreg 4.1 (2.5) 4.08 (2.1) 4.09 (2.2) 0.93 
 
a We used χ2 for categorical variables and T-test for CDPS risk score 
b Prior treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days in 34 days before 
admission. Codes used to define SUD treatment encounters are detailed in the appendix and include 1) 
a filled prescription for medication treatment, 2) a procedure code for SUD treatment, or 3) a clinic visit 
with an SUD ICD9 or 10 code. 
c Includes alcohol alone, stimulant alone, alcohol + stimulant, other 
d Includes opioids alone, opioids + alcohol, opioids + stimulant, opioids + alcohol + stimulant 
e Clackamas, Multnomah, and Washington counties 
f Medicare Severity Diagnosis Related Group (MS-DRG) 
g Chronic Illness & Disability Payment System (CDPS), continuous variable 
Abbreviations: IMPACT, Improving Addiction Care Team; SUD, substance use disorder 
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Table 2: Model results: Patient characteristics associated with treatment engagement  
  Unadjusted analyses Adjusted analyses 
  Total 
Engaged in 
Treatmenta 
Not engaged 
in Treatment aORb 95% CI 
Characteristic N N (%) N  (%) 
 
  
Control 416 97 (23.3) 349 (76.7) Ref. - - 
IMPACT 208 81 (38.9) 127 (61.1) 2.15 1.29 3.58 
No prior SUD treatmentc 517 101 (19.5) 416 (80.5) Ref. - - 
Prior SUD treatment 107 77 (72.0) 30 (28.0) 12.12 6.44 22.82 
SUD Type 
Non-opioid SUDd 186 36 (19.4) 150 (80.6) Ref. - - 
Any opioid SUDe 438 142 (32.4) 296 (67.58) 1.83 1.03 3.24 
Gender Female 248 73 (29.4) 175 (70.6) Ref. - - 
 Male 376 105 (27.9) 271 (72.1) 1.05 0.63 1.74 
Age 
(years) 
18-39 283 83 (29.3) 200 (70.7) Ref. - - 
40-64 341 95 (27.9) 246 (72.1) 0.83 0.48 1.40 
Race & 
Ethnicity 
Other 123 38 (30.9) 85 (69.1) Ref. - - 
White Non-Hispanic 501 140 (27.9) 361 (72.1) 0.92 0.53 1.62 
Region Non tri-county area 157 27 (17.2) 130 (82.8) Ref. - - 
  Portland tri-county areaf 467 151 (32.3) 316 (67.7) 1.74 0.90 3.34 
MS-DRG 
Categoryg 
Alcohol & related complications 130 35 (26.9) 95 (73.1) Ref. - - 
Endocarditis, osteomyelitis, sepsis 181 54 (29.8) 127 (70.2) 1.19 0.62 2.28 
Skin & soft tissue infections 26 12 (46.2) 14 (53.8) 2.36 0.88 6.32 
Non-valvular cardiovascular 30 13 (43.3) 17 (56.7) 2.07 0.80 5.36 
Orthopedic/Joint 29 6 (20.7) 23 (79.3) 0.49 0.12 2.02 
Other 228 58 (25.4) 170 (74.6) 0.98 0.49 1.94 
    Mean (SD)       
CDPS Risk Scoreh   4.04 (2.1) 4.11 (2.3) 1.05 0.93 1.19 
 
a Treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days within 34 days of discharge; 
Healthcare Effectiveness Data and Information Set (HEDIS) measure  
b Adjusted Odds Ratio (OR), adjusted for all variables in Table 2. 
c Prior Treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days in 34 days before admission 
d Includes alcohol alone, stimulant alone, alcohol + stimulant, other 
e Includes opioids alone, opioids + alcohol, opioids + stimulant, opioids + alcohol + stimulant 
f Clackamas, Multnomah, and Washington counties 
g Medicare Severity Diagnosis Related Group (MS-DRG) 
h Chronic Illness & Disability Payment System (CDPS), continuous variable 
Abbreviations: IMPACT, Improving Addiction Care Team; SUD, substance use disorder 
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Figure 1. IMPACT participant flow diagram. 
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Figure 2. 
 
 
 
Legend: Substance Use Disorder Treatment engagement over time, comparing IMPACT and controls.  
 
